BY HEALTHDAY: One-quarter of older adults with type 2 diabetes in the United States are tightly controlled using glucose-lowering medications with a high risk of hypoglycemia, according to a study published in the June issue of the Journal of the American Geriatrics Society.
Suzanne V. Arnold, M.D., from the University of Missouri-Kansas City, and colleagues examined the proportion of older adults with diabetes mellitus treated with tight glucose control and the factors associated with this practice. Data were obtained from 42,669 adults aged 75 and older with type 2 diabetes mellitus seen at 151 outpatient sites participating in the Diabetes Collaborative Registry. Patients were categorized according to glycosylated hemoglobin (HbA1c) and glucose-lowering medications. Groups were defined as poor control (HbA1c >9 percent), moderate control (HbA1c 8 to 9 percent), conservative control (HbA1c 7 to 8 percent), tight control with low-risk agents for hypoglycemia (HbA1c <7 percent), or tight control with high-risk agents. Another group was classified as diet control (HbA1c <7 percent taking no glucose-lowering medications). (read more)
BY HEALTH24: The risk factors for type 1 diabetes differ from those for type 2 and gestational diabetes.
Type 1 diabetes
Risk factors include:
- Family history. This increases the chances that a person will have islet-cell antibodies which, in turn, increase the risk of developing type 1 diabetes. Islet cells are clusters of cells in the pancreas that sense blood-glucose levels, and which produce insulin accordingly. Some people’s bodies produce antibodies that attack these cells.
- Race. Type 1 diabetes is more common among certain ethnicities. For example, in the United States, Caucasian people have a greater risk for type 1 diabetes than African-Americans and Hispanic Americans.
- Autoimmune disease. Type 1 diabetes can occur along with other autoimmune diseases like Grave’s disease (where the thyroid gland produces too much thyroid hormone) or vitiligo (a condition in which skin pigment is lost). (read more)
BY STEVE FORD: Clinicians can match type 2 diabetes patients to the right drug to improve blood glucose control by factoring in characteristics like body mass index and sex into prescribing decisions, say researchers.
They said their findings could dramatically improve benefits of drugs and reduce the risk of potentially harmful side-effects such as weight gain and hypoglycaemia, at no additional cost. (read more)
BY SHARMISTHA SARKAR: Diabetes is one of the fastest growing chronic diseases worldwide. According to the World Health Organization (WHO), the number of people suffering from diabetes is estimated to grow from 171 million in 2000 to 366 million in 2030. The condition is also the leading cause of diabetes retinopathy (DR). In some cases, swelling of blood vessels and secretion of fluid in the eye may occur. DR is the major cause of vision loss among middle-aged and elderly patients with type 1 or type 2 diabetes, globally.(read more)
BY REGINA SCHAFFER: The FDA has granted clearance for the Android version of the InPen app, making the device the first “smart” pen system for Android users, whereas the EMA has granted a CE mark allowing for availability in international markets, according to two press releases from Companion Medical.
The InPen system has been commercially available for iOS users since December 2017 and is the only FDA-cleared, smart insulin pen paired with an integrated diabetes management app. (read more)